文献速递哮喘

平滑肌Rac1在重症哮喘气道重塑中的关键作用

Essential role of smooth muscle Rac1 in severe asthma-associated airway remodelling.
PubMed 文献 · Thorax · 2021-02-04

该研究在重症哮喘患者支气管活检中观察到气道平滑肌细胞Rac1活性增高,Rac1通过STAT3通路调控平滑肌细胞增殖;在小鼠重症哮喘模型中,敲除平滑肌Rac1或雾化吸入Rac1抑制剂NSC23766可预防气道高反应性和平滑肌增生,并减少杯状细胞增生、上皮细胞肥大及嗜酸性粒细胞积聚,提示Rac1是治疗重症哮喘气道高反应性和气道重塑的潜在靶点。

要点

  • 重症哮喘患者气道平滑肌细胞中Rac1活性较对照组增高。
  • Rac1通过STAT3信号通路调控人气道平滑肌细胞增殖。
  • 雾化吸入Rac1抑制剂NSC23766可预防小鼠重症哮喘模型的气道高反应性和气道重塑。

核心结论

  • Rac1在重症哮喘患者气道中活性过高,是气道平滑肌细胞增殖所必需的,并因果性参与气道高反应性和气道重塑。
  • Rac1可能成为治疗重症哮喘患者气道高反应性和气道重塑的靶点。

研究设计与样本

  • 研究结合人支气管活检免疫荧光分析、体外人气道平滑肌细胞实验及小鼠重症哮喘模型体内实验。
  • 体外使用EHT1864抑制Rac1,体内采用平滑肌特异性Rac1敲除或雾化吸入NSC23766抑制Rac1。

主要发现

  • 人支气管活检免疫荧光显示重症哮喘患者气道平滑肌细胞Rac1活性较对照组增高。
  • EHT1864抑制Rac1表明Rac1信号通过STAT3通路控制有丝分裂刺激诱导的人气道平滑肌细胞增殖。
  • 小鼠模型中平滑肌特异性敲除Rac1或雾化NSC23766可预防气道高反应性和气道平滑肌增生。
  • Rac1抑制剂预防杯状细胞增生和上皮细胞肥大,而皮质类固醇治疗效果较弱。
  • 雾化NSC23766减少哮喘小鼠支气管肺泡灌洗液中嗜酸性粒细胞积聚。

临床怎么用

  • Rac1信号通路可作为重症哮喘气道重塑的潜在干预靶点。
  • 雾化吸入Rac1抑制剂在动物模型中显示可同时改善气道高反应性和气道重塑,但尚未应用于临床。

局限性

  • Rac1抑制剂的疗效证据主要来自小鼠模型,尚需临床研究验证。
  • 原文未报告人体内Rac1抑制剂的安全性及剂量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe asthma is a chronic lung disease characterised by inflammation, airway hyperresponsiveness (AHR) and airway remodelling. The molecular mechanisms underlying uncontrolled airway smooth muscle cell (aSMC) proliferation involved in pulmonary remodelling are still largely unknown. Small G proteins of the Rho family (RhoA, Rac1 and Cdc42) are key regulators of smooth muscle functions and we recently demonstrated that Rac1 is activated in aSMC from allergic mice. The objective of this study was to assess the role of Rac1 in severe asthma-associated airway remodelling. METHODS AND RESULTS: Immunofluorescence analysis in human bronchial biopsies revealed an increased Rac1 activity in aSMC from patients with severe asthma compared with control subjects. Inhibition of Rac1 by EHT1864 showed that Rac1 signalling controlled human aSMC proliferation induced by mitogenic stimuli through the signal transducer and activator of transcription 3 (STAT3) signalling pathway. In vivo, specific deletion of Rac1 in SMC or pharmacological inhibition of Rac1 by nebulisation of NSC23766 prevented AHR and aSMC hyperplasia in a mouse model of severe asthma. Moreover, the Rac1 inhibitor prevented goblet cell hyperplasia and epithelial cell hypertrophy whereas treatment with corticosteroids had less effect. Nebulisation of NSC23766 also decreased eosinophil accumulation in the bronchoalveolar lavage of asthmatic mice. CONCLUSION: This study demonstrates that Rac1 is overactive in the airways of patients with severe asthma and is essential for aSMC proliferation. It also provides evidence that Rac1 is causally involved in AHR and airway remodelling. Rac1 may represent as an interesting target for treating both AHR and airway remodelling of patients with severe asthma.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Dilasser F, Rose L, Hassoun D, et al. Essential role of smooth muscle Rac1 in severe asthma-associated airway remodelling. Thorax. 2021. PMID: 33542087. doi:10.1136/thoraxjnl-2020-216271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。